X

REGN

Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Transcript

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2025 Earnings Call dated Jan. 30, 2026 Corporate Participants: Ryan Crowe — Senior Vice…

Regeneron Full Year Revenue Totals $14.34 Billion

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares declined 2.61% during Friday’s trading session, following the release of the company’s fourth-quarter and…